Alphatec Holdings, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US02081G2012
USD
15.62
3.7 (31.04%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

859.26 k

Shareholding (Sep 2025)

FII

11.07%

Held by 87 FIIs

DII

64.33%

Held by 36 DIIs

Promoter

0.84%

How big is Alphatec Holdings, Inc.?

22-Jun-2025

As of Jun 18, Alphatec Holdings, Inc. has a market capitalization of $1.61 billion, classifying it as a Small Cap company. The latest four quarters show net sales of $642.26 million and a net profit of -$165.54 million.

As of Jun 18, Alphatec Holdings, Inc. has a market capitalization of 1,605.59 million, classifying it as a Small Cap company.<BR><BR>As of Jun 24, the sum of net sales for the latest four quarters is 642.26 million, while the sum of net profit for the same period is -165.54 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 9.43 million and total assets amounting to 775.71 million.

View full answer

What does Alphatec Holdings, Inc. do?

22-Jun-2025

Alphatec Holdings, Inc. is a medical technology company focused on products for spine disorder surgeries, with recent net sales of $169 million and a net loss of $52 million. It operates as a small-cap company with a market cap of approximately $1.61 billion.

Overview: <BR>Alphatec Holdings, Inc. is a medical technology company that designs, develops, manufactures, and markets products for the surgical treatment of spine disorders, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 169 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -52 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,605.59 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -6.44 <BR>Return on Equity: 232.00% <BR>Price to Book: -25.76<BR><BR>Contact Details: <BR>Address: 5818 El Camino Real, CARLSBAD CA: 92008 <BR>Tel: ['1 760 4319286', '1 760 4946790'] <BR>Fax: 1 302 6365454 <BR>Website: http://www.alphatecspine.com

View full answer

Who are in the management team of Alphatec Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Alphatec Holdings, Inc. includes Patrick Miles (Chairman, President, CEO), Mortimer Berkowitz (Lead Independent Director), David Pelizzon, Jeffrey Rydin, Evan Bakst, and Quentin Blackford (all Directors).

As of March 2022, the management team of Alphatec Holdings, Inc. includes the following individuals:<BR><BR>- Mr. Patrick Miles: Chairman of the Board, President, Chief Executive Officer<BR>- Mr. Mortimer Berkowitz: Lead Independent Director<BR>- David Pelizzon: Director<BR>- Mr. Jeffrey Rydin: Director<BR>- Mr. Evan Bakst: Independent Director<BR>- Mr. Quentin Blackford: Independent Director

View full answer

Should I buy, sell or hold Alphatec Holdings, Inc.?

22-Jun-2025

Is Alphatec Holdings, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Alphatec Holdings, Inc. shows a mildly bullish trend overall, with mixed signals from MACD indicators and moving averages, while underperforming the S&P 500 recently but significantly outperforming it year-to-date.

As of 3 October 2025, the technical trend for Alphatec Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The Bollinger Bands and moving averages are both mildly bullish on the daily and weekly charts. KST shows bullish momentum in both weekly and monthly perspectives. However, Dow Theory presents a mildly bearish stance on the weekly chart but is bullish monthly. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -7.80% and -17.07% respectively, while it has significantly outperformed the benchmark on a year-to-date basis with a return of 48.15% compared to the S&P 500's 14.18%. Overall, the current technical stance is mildly bullish, driven by the monthly bullish indicators and the daily moving averages.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Positive results in Jun 25

  • OPERATING CASH FLOW(Y) Highest at USD 15.69 MM
  • RAW MATERIAL COST(Y) Fallen by -4.19% (YoY)
  • CASH AND EQV(HY) Highest at USD 310.31 MM
2

Risky - Negative EBITDA

3

Market Beating Performance

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,530 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

11.69

stock-summary
Return on Equity

-325.84%

stock-summary
Price to Book

72.06

Revenue and Profits:
Net Sales:
197 Million
(Quarterly Results - Sep 2025)
Net Profit:
-29 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
61.53%
0%
61.53%
6 Months
61.87%
0%
61.87%
1 Year
52.39%
0%
52.39%
2 Years
3.31%
0%
3.31%
3 Years
111.37%
0%
111.37%
4 Years
10.31%
0%
10.31%
5 Years
202.71%
0%
202.71%

Alphatec Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
41.26%
EBIT Growth (5y)
-175.21%
EBIT to Interest (avg)
-10.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-6.44
Sales to Capital Employed (avg)
1.01
Tax Ratio
0.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
84.57%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-30.22
EV to EBIT
-19.64
EV to EBITDA
-72.82
EV to Capital Employed
6.74
EV to Sales
3.56
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-34.32%
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 59 Schemes (23.76%)

Foreign Institutions

Held by 87 Foreign Institutions (11.07%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 30.39% vs 27.39% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 27.78% vs 7.26% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "196.50",
          "val2": "150.70",
          "chgp": "30.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "11.00",
          "val2": "-8.80",
          "chgp": "225.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "12.90",
          "val2": "6.60",
          "chgp": "95.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.50",
          "val2": "-3.00",
          "chgp": "-116.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-28.60",
          "val2": "-39.60",
          "chgp": "27.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-47.90%",
          "val2": "-203.50%",
          "chgp": "15.56%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 26.81% vs 37.45% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 13.13% vs -23.33% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "611.60",
          "val2": "482.30",
          "chgp": "26.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-39.60",
          "val2": "-88.60",
          "chgp": "55.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "24.90",
          "val2": "16.60",
          "chgp": "50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.30",
          "val2": "-25.10",
          "chgp": "47.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-162.10",
          "val2": "-186.60",
          "chgp": "13.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-201.00%",
          "val2": "-307.50%",
          "chgp": "10.65%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoYstock-summary

Sep'25
Sep'24
Change(%)
Net Sales
196.50
150.70
30.39%
Operating Profit (PBDIT) excl Other Income
11.00
-8.80
225.00%
Interest
12.90
6.60
95.45%
Exceptional Items
-6.50
-3.00
-116.67%
Consolidate Net Profit
-28.60
-39.60
27.78%
Operating Profit Margin (Excl OI)
-47.90%
-203.50%
15.56%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2025 is 30.39% vs 27.39% in Sep 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 27.78% vs 7.26% in Sep 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
611.60
482.30
26.81%
Operating Profit (PBDIT) excl Other Income
-39.60
-88.60
55.30%
Interest
24.90
16.60
50.00%
Exceptional Items
-13.30
-25.10
47.01%
Consolidate Net Profit
-162.10
-186.60
13.13%
Operating Profit Margin (Excl OI)
-201.00%
-307.50%
10.65%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 26.81% vs 37.45% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 13.13% vs -23.33% in Dec 2023

stock-summaryCompany CV
About Alphatec Holdings, Inc. stock-summary
stock-summary
Alphatec Holdings, Inc.
Pharmaceuticals & Biotechnology
Alphatec Holdings, Inc. is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc. and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures. Its products include Cervical and Cervico-Thoracic Products, which include Trestle Luxe Anterior Cervical Plate System and Pegasus Anchored Cervical Interbody; Thoracolumbar Fixation Products, which include Arsenal Degenerative System and OsseoScrew Spinal Fixation System; Spinal Spacers, which include Battalion Universal Spacer System and Alphatec Solus Locking ALIF Spinal Spacer; minimally invasive surgery Products, which include Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System, and Biologics, which include Neocore Osteoconductive Matrix.
Company Coordinates stock-summary
Company Details
5818 El Camino Real , CARLSBAD CA : 92008
stock-summary
Tel: 1 760 43192861 760 4946790
stock-summary
Registrar Details